OMass Therapeutics
OMass Therapeutics develops small-molecule medicines for endocrine and immune diseases using a platform that measures drug targets in their biological surroundings.
$310MSeries C
ParticipantSH
SV Health Investors
Activity from announced rounds
Activity in this selectionSeries C+
- Rounds participated in
- 2
- Confirmed lead rounds
- 0 1 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $625M 2 disclosed · full round size, not this investor’s share